Publications


AIBL refereed journal articles by year. Conference proceedings, abstracts and other publications are excluded.

2017

183. FERREIRA D, HANSON O, BARROSO J, MOLINA Y, MACHADO A, HERNÁNDEZ-CABRERA JA, MUEHLCOECK J-S, STOMRUD E, NÄGGA K, LINDBERG O, AMESD D, KALPOUZOS G, FRATIGLIONI L, BÄCKMAN L, LUAKKA EJ, GRAFF C, MECOCCI P, VELLAS B, TSOLAKI M, KLOSZEWA I, SOININEN H, LOVESTONE S, AHLSTRÖM H, LIND L, LARSSON E-M, WAHLUND L-O, SIMMONS A & WESTMAN E. (2017) The interactive effect of demographic and clinical factors on hippocampal volume: a multicohort study on 1958 cognitively normal individuals. Hippocampus, in press, accepted February 2017.

182. FERREIRA D, FALAHATI F, LINDEN C, BUCKLEY R, ELLIS K, SAVAGE G, VILLEMAGNE V, ROWE CC, AMES D, SIMMONS A & WESTMAN E. (2017) A ‘Disease Severity Index’ to identify individuals with subjective memory decline that will progress to mild cognitive impairment or dementia. Scientific Reports, in press.

181. Pietrzak RH, Laws SM, Lim YY, Bender SJ, Porter T, Doecke J, Ames D, Fowler C, Masters CL, Milicic L, Rainey-Smith S, Villemagne VL, Rowe CC, Martins RN, Maruff P for the Australian Imaging, Biomarkers and Lifestyle Research Group. Plasma cortisol, brain amyloid-β, and cognitive decline in preclinical Alzheimer’s disease: A 6-year prospective cohort study. Biol Psychiat: Cog Neurosci Neuroimaging. 2017; 2: 45-52

180. O’Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele, Zetterberg H, Lewczuk, Posner H, Hall J, Johnson L, Fong YL, Luthman J, Jeromin A, Batrla-Utermann R, Villarreal A, Britton G, Snyder PJ, Henriksen K, Grammas P, Gupta V, Martins R, Hampel H, and the Biofluid Based Biomarker Professional Interest Area. Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alz Dement. 2017; 13: 45-58

179. Villemagne VL, Doré V, Bourgeat P, Burnham SC, Laws S, Salvado O, Masters CL, Rowe CC. Aβ-amyloid and tau imaging in dementia. Sem Nucl Med. 2017; 47: 75-88

2016

178. HOLMES SE, ESTERLIS I, MAZURE CM, LIM YY, AMES D, RAINEY-SMITH S, MARTINS RN, SALVADO O, DORÉ V, VILLEMAGNE V, ROWE CC, LAWS S, MASTERS CL, MARUFF P, PIETRZAK RH & the AIBL RESEARCH GROUP (2106) β-amyloid, APOE and BDNF genotype, and depressive and anxiety symptoms in cognitively normal older women and men. American Journal of Geriatric Psychiatry, 24: 1191-1195. doi: 10.1016/j.jagp.2016.08.007

177. Roberts BR, Doecke JD, Rembach A, McLean CA, Volitakis I, Masters CL, Bush AI, Hare DJ, and the AIBL Research Group. Altered levels of potassium and rubidium levels in the Alzheimer’s disease brain, Blood and CSF. Acta Neuropath Comm. 2016; 4: 119
176. Westwood S, Leoni E, Hye A, Lynham S, Khondoker MR, Ashton NJ, Kiddle SJ, Baird AL, Sainz-Fuertes R, Leung R, Graf J, Hehir CT, Baker D, Cereda C, Bazenet C, Ward M, Thambisetty M, Lovestone S. Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly. J Alz Dis. 2016; 52: 561-72

175. Roberts BR, Doecke JD, Rembach A, Yévenes LF, Fowler CJ, McLean CA, Lind M, Volitakis I, Masters CL, Bush AI, Hare DJ, and the AIBL Research Group. Rubidium and potassium levels are altered in Alzheimer’s disease brain and blood but not in cerebrospinal fluid. Acta Neuropath Comm. 2016; 4: Doi: 10.1186/s40478-016-0390-8

174. Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Porter T, Ames D, Fowler C, Rainey-Smith S, Snyder PJ, Martins RN, Salvado O, Bourgeat P, Rowe CC, Masters CL, and Maruff P. Aβ-related memory decline in APOE ε4 noncarriers: Implications for Alzheimer disease. Neurology. 2016; 86: 1635-1642

173. François M, Fenech MF, Thomas P, Hor M, Rembach A, Rainey-Smith S, Masters CL, Ames D, Rowe CC, Macaulay SL, The Australian Imaging, Biomarkers and Lifestyle (AIBL) study research group. High content, multi-parameter analyses in buccal cells to identify Alzheimer’s disease. Current Alzheimer Research. 2016; 13: 787-799

172. Brown BM, Rainey-Smith SR, Bucks RS, Weinborn M, Martins RN. Exploring the bi-directional relationship between sleep and beta-amyloid. Current Opinion in Psychiatry 2016; 29: 397-401

171. Chong TWH, Loi SM, Lautenschlager NT, Ames D. Therapeutic advances and risk factor management: our best chance to tackle dementia? MJA 2016; 204: 91-92.

170. Harrington KD, Lim YY, Ames D, Hassenstab J, Rainey-Smith S, Robertson J, Salvado O, Masters CL, and Maruff P for the AIBL Research Group. Using robust normative data to investigate the neuropsychology of cognitive aging. Arch Clin Neuropsych. 2016: 1-13.

169. Heffernan AL, Chidgey C, Peng P, Masters CL, Roberts BR. The neurobiology and age-related prevalence of the ε4 allele of apolipoprotein E in Alzheimer’s disease cohorts. J Mol Neurosci. 2016; 60: 316-324.

168. Buckley RF, Villemagne VL, Masters CL, Ellis KA, Rowe CC, Johnson K, Sperling R, Amariglio R. A conceptualization of the utility of subjective cognitive decline in clinical trials of preclinical Alzheimer’s disease. J Mol Neurosci. 2016; 60: 354-361.

167. Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Ames D, Fowler C, Rainey-Smith S, Snyder PJ, Bourgeat P, Martins RN, Salvado O, Rowe CC, Masters CL, Maruff P on behalf of the AIBL research group. Performance on the Cogstate Brief Battery is related to amyloid levels and hippocampal volume in very mild dementia. J Mol Neurosci. 2016; 60: 362:370.

166. Yassi N, Desmond PM, Masters CL. Magnetic resonance imaging of vascular contributions to cognitive impairment and dementia. J Mol Neurosci. 2016; 60: 349-353.

165. Baker J, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, Maruff P. Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alz Dement. 2016; Doi:10.1016/j.dadm.2016.09.002.

164. Albrecht MA, Masters CL, Ames D, Foster JK and the AIBL research group. Impact of mild head injury on neuropsychological performance and cognitive decline in cognitively healthy older adults: longitudinal assessment in the AIBL cohort. Frontiers in Aging Neuroscience. 2016; 8: doi: 10.3389/fnagi.2016.00105

163. Burnham SC, Rowe CC, Baker D, Bush AI, Doecke JD, Faux NG, Laws SM, Martins RN, Maruff P, Macaulay SL, Rainey-Smith S, Savage G, Ames D, Masters CL, Wilson W, Villemagne VL. Predicting Alzheimer disease from a blood-based biomarker profile: A 54 month follow up. Neurology. 2016; 87: 1093-1101.

162. Gupta VB, Doecke JD, Hone E, Pedrini S, Laws SM, Thambisetty M, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Macaulay SL, Rembach A, Rainey-Smith SR, Martins RN and the AIBL Research Group. Plasma apolipoprotein J as a potential biomarker for Alzheimer’s disease: Australian Imaging Biomarkers and Lifestyle Study of aging. Alz Dementia: Diagnosis, Assessment and Disease Monitoring. 2016; 3: 18-26.

161. Lim YY, , Snyder PJ, Pietrzak RH, Ukiqi A, Villemagne VL, Ames D, Salvado O, Bourgeat P, Martins RN, Masters CL, Rowe CC, Maruff P for the AIBL Research Group. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer’s disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alz Dementia. 2016; 2: 19-26.

160. Brown BM, Rainey-Smith SR, Villemagne VL, Weinborn M, Bucks RS, Sohrabi HR, Laws SM, Taddei K, Macaulay L, Ames D, Fowler C, Maruff P, Masters CL, Rowe CC, Martins RN, and the AIBL Research Group. The relationship between sleep quality and brain amyloid burden. Sleep. 2016; 39: 1063-1068.

159. Gu BJ, Huang X, Ou A, Rembach A, Fowler C, Avula PK, Horton A, Doecke JD, Villemagne VL, Macaulay SL, Maruff P, Fletcher EL, Guymer R, Wiley JS, Masters CL. The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study. Innate phagocytosis by peripheral blood monocytes is altered in Alzhiemer’s disease. Acta Neuropath 2016; 132: 377-389.

158. Harrington KD, Gould E, Lim YY, Ames D, Pietrzak RH, Rembach A, Rainey-Smith S, Martins RN, Salvado O, Villemagne VL, Rowe CC, Masters CL and Maruff P for the AIBL Research Group. Amyloid burden and incident depressive symptoms in cognitively normal older adults. Int J Geriat Psychiat. 2016; Doi:10.1002/gps.4489.

157. Buckley RF, Maruff P, Ames D, Bourgeat P, Martins RN, Masters CL, Rainey-Smith S, Lautenschlager N, Rowe CC, Savage G, Villemagne VL, Ellis KA, and other co-investigators in the AIBL study. Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer’s disease. Alz & Dement. 2016; 12: 796 – 804.

156. Cerin E, Rainey-Smith SR, Ames D, Lautenschlager NT, Macaulay L, Fowler C, Robertson JS, Rowe CC, Maruff P, Martins RN, Masters CL, Ellis KA. Associations of neighbourhood environment with brain imaging outcomes in the AIBL cohort. Alz & Dement. 2016; Doi: 10.1016/j.jalz.2016.06.2364

155. Chételat G, Ossenkoppele R, Villemagne VL, Perrotin A, Landeau B, Mézenge F, Jagust WJ, Dore V, Miller BL, Egret S, Seeley WW, van der Flier WM, La Joie R, Ames D, van Berckel BNM, Scheltens P, Barkhof F, Rowe CC, Masters CL, de La Sayette V, Bouwman F, Rabinovici GD. Atrophy, hypometabolism and clinical trajectories in amyloid-negative Alzheimer’s disease patients. Brain. 2016; 139: 2528-2539

154. Burnham SC, Bourgeat P, Doré V, Savage G, Brown B, Laws S, Maruff P, Salvado O, Ames D, Martins RN, Masters CL, Rowe CC, Villemagne VL for the AIBL Research Group. Clinical and cognitive trajectories in cognitively elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. Lancet Neurol. 2016; 15: 1044 – 1053. [See also Commentary: Bischof GN. Alzheimer’s disease risk: amyloid versus neurodegeneration. Lancet Neurol. 2016; 15: 1000-1001.

153. Zwan MD, Villemagne VL, Dore V, Buckley R, Bourgeat P, Veljanoski R, Salvado O, Williams R, Margison L, Rembach A, Macaulay L, Martins R, Ames D, van der Flier WM, Ellis KA, Scheltens P, Masters CL, Rowe CC, for the AIBL study. Subjective memory complaints in APOE ε4 carriers are associated with high amyloid-β burden. J Alz Dis. 2016: 49: 1115-1122.

2015

152. Gardener SL, Rainey-Smith SR, Macaulay SL, Taddei K, Rembach A, Maruff P, Ellis KA, Masters CL, Rowe CC, Ames D, Keogh JB, Martins RN. Comparative analysis of the cancer council of Victoria and the online commonwealth scientific and industrial research organisation FFQ. The British Journal of Nutrition 2015; 114:1683-1693.

151. Thai C, Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Ames D, Ellis KA, Rainy-Smith SR, Harrington K, Martins RN, Masters CL, Rowe CC, and Maruff P, for the Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. Amyloid-Related Memory Decline in Preclinical Alzheimer’s Disease Is Dependent on APOE epsilon4 and Is Detectable over 18-Months. PLoS One 2015; 10: e0139082. doi: 10.1371/journal.pone.0139082.

150. Buckley RF, Saling MM, Ellis KA, Rowe CC, Maruff P, Macaulay SL, Martins RN, Masters CL, Savage G, Rainey-Smith SR, Rembach A, Ames D, on behalf of the Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment. Age Ageing 2015; 44; 1012-1019.

149. Rembach A, Evered LA, Li Q-X, Nash T, Vidaurre L, Fowler CJ, Pertile KK, Rumble RL, Trounson B, Maher S, Mooney F, Farrow M, Taddei K, Rainey-Smith S, Laws SM, Macaulay L, Wilson W, Darby D, Martins R, Ames D, Collins S, Silbert B, Masters CL, Doecke JD and the AIBL Research Group. Alzheimer’s disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology. Alzheimers Res Ther 2015; 7: doi:10.1186/s13195-015-0157-7.

148. Poole SG, Bell JS, Jokanovic N, Kirkpatrick CM, Dooley MJ. A systematic review of medication exposure assessment in prospective cohort studies of community dwelling older Australians. PLoS One 2015; doi:10.1371/journal.pone.0124247.

147. Hendrix JA, Finger B, Weiner MW, Frisoni GB, Iwatsubo T, Rowe CC, Kim SY, Guinjoan SM, Sevlever G, Carrillo MC. The Worldwide Alzheimer’s Disease Neuroimaging Initiative: An update. Alzheimers Dement 2015; 11:850-859.

146. Voyle N, Baker D, Burnham SC, Covin A, Zhang Z, Sangurdekar DP, Tan Hehir CA, Bazenet C, Lovestone S, Kiddle S, Dobson RJ. Blood Protein Markers of Neocortical Amyloid-beta Burden: A Candidate Study Using SOMAscan Technology. J Alzheimers Dis 2015; 46:947-961.

145. Cheng L, Doecke JD, Sharples R, Villemagne VL, Fowler CJ, Rembach A, Martins RN, Rowe C, Macaulay SL, Masters CL, Hill AF, for the Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Molec Psych. 2015; 20: 118-1196.

144. Pietrzak RH, Lim YY, Ames D, Harrington K, Restrepo C, Martins RN, Rembach A, Laws SM, Masters CL, Villemagne VL, Rowe CC, Maruff P, for the Australian Imaging, Biomarkers and Lifestle (AIBL) Research Group. Trajectories of memory decline in preclinical Alzheimer’s disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiol Aging. 2015: 36; 1231-1238.

143. Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PJ, Ames D, Ellis KA, Harrington K, Rembach A, Martins RN, Rowe CC, Masters CL, Maruff P for the AIBL research group. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer’s disease. Molec Pscyh. 2015: 20; 1322-1328

142. Burnham S, Raghavan N, Wilson W, Baker D, Ropacki MT, Novak G, Ames D, Ellis K, Martins R, Maruff P, Masters C, Romano G, Rowe C, Savage G, Twyman R, Macaulay L, Narayan V, the Alzheimer’s Disease Neuroimaging Intiative and the AIBL Research Group. Novel statistically-derived composite measures for assessing the efficacy of disease-modifying therapies in prodromal AD trials: An AIBL study. J Alz Dis. 2015: 46; 1079-1089.

141. Leifert W, Nguyen T, Rembach A, Martins R, Masters CL, Ames D, Rowe CC, Macaulay SL, François M, Fenech M. Buccal cell cytokeratin 14 correlates with multiple blood biomarkers of Alzheimer’s disease risk. J Alz Dis. 2015: 48: 443-452.

140. Merkel B, Steward C, Vivash L, Malpas CB, Phal P, Moffat BA, Cox KL, Ellis KA, Ames D, Cyarto E, Lai MM, Rowe CC, Sharman M, Szoeke C, Masters CL, Lautenschlager NT and Desmond P. Semi-automated hippocampal segmentation in people with cognitive impairments using an age appropriate template for registration. J Mag Res Imaging. Doi:10.1002/jmri.24966.

139. Lim YY, Villemagne VL, Pietrzak RH, Ames D, Ellis KA, Harrington K, Snyder PJ, Martins RN, Masters CL, Rowe CC, Maruff P for the Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer’s disease. Neurobiology Aging. 2015: 36; 1239-1244.

138. Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton K, Pertile K, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws S, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S for the AIBL Research Group. Alzheimer disease normative CSF biomarkers validated in PET Aβ characterized subjects from the Australian Imaging, Biomarker and Lifestyle (AIBL) study. J Alz Dis. 2015: 48; 175-187.

137. Gupta VB, Wilson AC, Burnham S, Hone E, Pedrini S, Laws SM, Lim WLF, Rembach A, Rainey-Smith S, Ames D, Cobiac L, Macaulay L, Masters CL, Rowe CC, Bush AI, Martins RN and the AIBL Research Group. Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. Alz Res Therapy. 2015; 7: 16. Doi: 10.1186/s13195-015-0105-6.

136. Hare DJ, Doecke JD, Faux NG, Rembach A, Volitakis I, Fowler CJ, Grimm R, Doble PA, Cherny RA, Masters CL, Bush AI, Roberts BR. Decreased plasma iron in Alzheimer’s disease is due to transferrin desaturation. ACS Chem Neurosci. 2015; 6: 398-402.

135. Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R, Masters CL, Ames D, Ellis KA, Rowe CC, Salvado O, Fripp J for the AIBL research group. Comparison of MR-less PiB SUVR quantification methods. Neurobiol of Aging. 2015; 36 Suppl 1: S159-S166.

134. Laske C, Sohrabi HR, Frost SM, Lopez-de-Ipina K, Garrard P, Buscema M, Dauwels J, Soekadar SR, Mueller S, Linnemann C, Bridenbaugh SA, Kanagasingam Y, Martins RN, O’Bryant SE. Innovative diagnostic tools for early detection of Alzheimer’s disease. Alzheimers Dement. 2015; 11: 561-78.

133. O’Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, Bazenet C, Soares H, Lovestone S, Hampel H, Montine T, Blennow K, Foroud T, Carrillo M, Graff-Radford N, Laske C, Breteler M, Shaw L, Trojanowski J Q, Schupf N, Rissman RA, Fagan A M, Oberoi P, Umek R, Weiner MW, Grammas P, Posner H, Martins R, for the STAR-B and BbBIG working groups. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement. 2015; 11: 549-560.

132. Buckley RF, Ellis KA, Ames D, Rowe CC, Lautenschlager NT, Maruff P, Villemagne V, Macaulay SL, Szoeke C, Martins RN, Masters CL, Savage G, Rainey-Smith SR, Rembach A, Saling MM, the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Phenomenological characterisation of memory complaints in preclinical and prodromal Alzheimer’s disease. Neuropsychology. 2015; 29: 571-581.

131. Lim YY, Pietrzak RH, Bourgeat P, Ames D, Ellis KA, Rembach A, Harrington K, Salvado O, Martins RN, Snyder PJ, Masters CL, Rowe CC, Villemagne VL, Maruff P. Relationships between performance on the Cogstate Brief Battery, neurodegeneration and Aβ accumulation in cognitively normal older adults and adults with MCI. Arch Clin Neuropsych 2015; 30: 49-58.

130. Watt AD, Perez KA, Ang C-S, O’Donnell P, Rembach A, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Faux NG, Masters CL, Villemagne VL, Barnham KJ. Peripheral α-defensins 1 and 2 are elevated in Alzheimer’s disease. J Alz Dis. 2015; 44: 1131-1143.

129. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, Rowe CC, Skovronsky DM, Mintun MA. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alz & Dem. 2015: 11; 1-15, e1-4.

128. Pietrzak RH, Lim YY, Neumeister A, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Restrepo C, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P for the Australian Imaging, Biomarkers and Lifestyle Research Group. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer’s disease: A multicentre, prospective cohort study. JAMA Psychiatry. 2015; 72: 284-291.

127. Hollands S, Lim YY, Buckley R, Pietrzak RH, Snyder PJ, Ames D, Ellis KA, Harrington K, Lautenschlager N, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P, for the AIBL Research Group. Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. J Alz Dis. 2015; 43: 677-686.

126. Ong KT, Villemagne VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, Stephens AW, Seibyl J, Dinkelborg LM, Reininger CB, Putz B, Rohde B, Masters CL, Rowe CC. Aβ imaging with 18F-florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. J Neurol Neurosurg Psychiat. 2015; 86: 431-436.

125. Albrecht MA, Szoeke C, Maruff P, Savage G, Lautenschlager N, Ellis K, Taddei K, Martins R, Masters C, Ames D, Foster JK, the AIBL Research Group. Longitudinal cognitive decline in the AIBL cohort: the role of APOE ε4 status. Neuropsychologia. 2015; 75: 411-419.

124. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early days and future perspectives. Lancet Neurol. 2015; 14: 114-124.

123. Rembach A, Stingo FC, Peterson C, Vannucci M, Do K-A, Wilson WJ, Macaulay SL, Ryan TM, Martins RN, Ames D, Masters CL, Doecke JD and the AIBL Research Group. Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer’s Disease. J Alz Dis. 2015; 44: 917-925.

122. Gardener SL, Rainey-Smith SR, Barnes MB, Sohrabi HR, Weinborn M, Lim YY, Harrington K, Taddei K, Gu Y, Rembach A, Szoeke C, Ellis KA, Masters CL, Macaulay SL, Rowe CC, Ames D, Keogh JB, Scarmeas N, Martins RN for the AIBL Research Group. Dietary patterns and cognitive decline in an Australian study of ageing. Molec Psych. 2015; 20: 860-866.

2014

121. Chong TWH, Doyle CJ, Cyarto EV, Cox KL, Ellis KA, Ames D, Lautenschlager N and the AIBL Research Group. Physical activity program preferences and perspectives of older adults with and without cognitive impairment. Asia Pac Psychiatry. 2014; 6: 179-190.

120. Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Doré V, Yanai K, Masters CL, Kudo Y, Rowe CC, Okamura N. In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease. Eur J Nucl Med Molec Imag. 2014; 41: 816-826.

119. Okamura N, Furumoto S, Fodero-Tavoletti M, Mulligan R, Harada R, Yates P, Pejoska S, Kudo Y, Masters C, Yanai K, Rowe C, Villemagne V. Noninvasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014; 137: 1762-1771.

118. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert M-O, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014; 13: 614-629.

117. Johnson P, Vandewater L, Wilson W, Maruff P, Savage G, Graham P, Macaulay SL , Ellis KA, Szoeke C, Martins RN, Rowe CC, Masters CL, Ames D, Zhang P. Genetic algorithm with logistic regression for prediction of progression of Alzheimer’s disease. BMC Bioinformatics. 2014; 15: Suppl 16: S11.

116. Buckley RF, Saling MM, Irish M, Ames D, Rowe CC, Villemagne VL, Lautenschlager NT, Maruff P, Macaulay SL, Martins RN, Szoeke C, Masters CL, Rainey-Smith SR, Rembach A, Savage G, Ellis KA and the Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Autobiographical narratives relate to Alzheimer’s disease biomarkers in older adults. Int Psychogeriatrics. 2014; 26:1737-1746.

115. Brown BM, Bourgeat P, Peiffer JJ, Burnham S, Laws SM, Rainey-Smith SR, Bartrés-Faz D, Villemagne VL, Taddei K, Rembach A, Bush A, Ellis KA, Macaulay SL, Rowe CC, Ames D, Masters CL, Maruff P, Martins RN for the AIBL Research Group. Influence of BDNF Val66Met on the relationship between physical activity and brain volume. Neurol 2014; 83: 1345-1352.

114. Rembach A, Watt AD, Wilson WJ, Rainey-Smith S, Ellis KA, Rowe CC, Villemagne VL, Macaulay LS, Bush AI, Martins RN, Ames D, Masters CL, Doecke JD and the AIBL research group. An increased Neutrophil-Lymphocyte ratio in Alzheimer’s disease is a function of age and is weakly correlated with neocortical amyloid accumulation. J Neuroimmunology. 2014; 273: 65-71.

113. Rembach A, Hare DJ, Doecke JD, Burnham SC, Volitakis I, Fowler CJ, Cherny RA, McLean C, Grimm R, Martins R, Ames D, Masters CL, Bush AI, Roberts BR. Decreased serum zinc is an effect of ageing and not Alzheimer’s disease. Metallomics: integrated biometal science. 2014; 6: 1216-1219.

112. Villemagne VL, Dorѐ V, Yates P, Brown B, Mulligan R, Bourgeat P, Veljanoski R, Rainey-Smith SR, Ong K, Rembach A, Williams R, Burnham SC, Laws SM, Salvado O, Taddei K, Macaulay SL, Martins RN, Ames D, Masters CL, Rowe CC. En attendant centiloid. Advances in Research. 2014; 2: 723-729.

111. Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS for the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing: the Alzheimer’s Disease Neuroimaging Initiative; and the Alzheimer’s Disease Cooperative Study. The preclinical Alzheimer cognitive composite measuring amyloid-related decline. JAMA Neurol. 2014: 71: 961-970.

110. Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, Rentz DM, Johnson KA, Sperling RA, for the Alzheimer’s Disease Neuroimaging Initiative, the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing, and the Harvard Aging Brain Study. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurol. 2014; 82: 1760-1767.

109. Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, Bush AI, Doecke J, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rowe C, Salvado O, Macaulay L, Masters CL, Villemagne V and the AIBL Research Group. A blood based predictor for neocortical Amyloid burden in Alzheimer’s disease: Results from the AIBL study. Mol Psychiatry. 2014; 19: 519-526.

108. Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li Q-X, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KA, Szoeke C, Macaulay L, Rowe CC, Villemagne VL, Ames D, Martin RN, Bush AI, Masters CL and the AIBL research group. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer’s disease. Alz Dement 2014; 10: 53-61.

107. Brodaty H, Mothakunnel A, De Vel-Palumbo M, Ames D, Ellis K, Reppermund S, Kochan NA, Savage G, Troller J, Crawford J, Sachdev PS. Influence of population versus convenience sampling on sample characteristics in studies of cognitive ageing. Ann Epidemiol. 2014; 24: 63-71.

106. Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, Maruff P, Ames D, Rowe CC, Macaulay SL, Bush AI, Martins RN, Masters CL, Doecke JD. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer’s disease as measured by cognitive decline and change in neocortical amyloid burden. J Alzheimers Dis. 2014; 40: 95-104.

105. Lim YY, Maruff P, Pietrzak RH, Ellis KA, Darby D, Ames D, Harrington K, Martins RN, Masters CL, Szoeke C, Savage G, Villemagne VL, Rowe CC for the AIBL Research Group. Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer’s disease. Alzheimers Dement. 2014; 10: 743-751.

104. Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, Harrington K, Bourgeat P, Salvado O, Bush AI, Martins RN, Masters CL, Rowe CC, Maruff P for the AIBL Research Group. Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer’s disease: A preliminary study. PLoS One 2014; 9: e86498. Doi:10.1371/journal.pone.0086498.

103. Yates PA, Desmond PM, Phal PM, Steward C, Szoeke C, Salvado O, Ellis KA, Martins RN, Masters CL, Ames D, Villemagne VL, Rowe CC for the AIBL research group. Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology. 2014; 82: 1266-1273.

102. Fodero-Tavoletti MT, Furumoto S, Taylor L, McLean CA, RS Mulligan, Birchall I, Harada R, Masters CL, Yanai K, Kudo Y, Rowe CC, Okamura N and Villemagne VL. Assessing THK 523 selectivity for tau deposits in Alzheimer’s disease and non-Alzheimer disease tauopathies. Alzheimers Res Ther. 2014; 6: 11.

101. Moore E, Ames D, Mander AG, Carne RP, Brodaty H, Woodward M, Boundy K, Ellis K, Bush AI, Faux NG, Martins R, Masters CL, Rowe C, Szoeke C, Watters DA, and the AIBL investigators. Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. J Alzheimers Dis. 2014; 39:661-668.

100. Ellis K, Szoeke C, Bush A, Darby D, Graham P, Lautenschlager N, Macaulay L, Martins R, Maruff P, Masters C, McBride S, Rainey-Smith S, Rembach A, Robertson J, Rowe C, Savage G, Woodward M, Wilson W, Villemagne V, Zhang P, Ames D and the AIBL investigators. Rates of diagnostic transition and cognitive change at 18 month follow up among 1112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship study of Ageing (AIBL). Int Psychogeriatr. 2014; 26: 543-554.

99. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chѐtelat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, dela Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M and the Subjective Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alz & Dement. 2014; 10: 844-852.

98. Verdile G, Laws SM, Henley D, Ames D, Bush AI, Ellis KA, Faux NG, Gupta VB, Li Q-X, Masters CL, Pike KE, Rowe CC, Szoeke C, Taddei K, Villemagne VL, and Martins RN for the AIBL Research Group. Associations between gonadotropins, testosterone, and β amyloid in men at risk of Alzheimer’s Disease. Mol Psych. 2014; 19: 69-75.

97. Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeke C, Martins RN, Masters CL, Villemagne VL, Rowe CC for the AIBL Research Group. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease. Brain 2014; 137: 221-223.

96. Yates, P.A., Villemagne, V.L., Ellis, K.A., Desmond, P.M., Masters, C.L. and Rowe, C.C. (2014). Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. Frontiers in Neurology, 4, 205.

95. Buckley RF, Saling MM, Irish M, Ames D, Rowe CC, Lautenschlager NT, Maruff P, Macaulay SL, Martins RN, Masters CL, Rainey-Smith SR, Rembach A, Savage G, Szoeke C, Ellis KA. Personal memory function in Mild Cognitive Impairment and Subjective Memory Complaints: Results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. J Alzheimers Dis. 2014; 40: 551 – 561.

94. Pietrzak RH, Scott JC, Neumeister A, Lim YY, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeke C, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P; the Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year perspective cohort study. Br J Psychiatry. 2014; 204: 400-1.

93. Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Macaulay SL, Ames D, Masters CL, Ellis KA, Villemagne VL, Rowe CC, Fripp J, AIBL Research Group. MR-less surface-based amyloid assessment based on 11C PiB PET. PLOS One. 2014; 9: e84777.

92. Rembach A. Alzheimer disease: the search for a blood-based biomarker for Alzheimer disease. Nat Rev Neurol. 2014; 10: 618-619.

91. Faux NG, Rembach A, Wiley J, Ellis KA, Ames D, Fowler CJ, Martins RN, Pertile KK, Rumble RL, Trounson B, Masters CL, The AIBL Research Group, Bush AI. An anemia of Alzheimer’s disease. Mol Psychiatry. 2014; 19: 1227-1234.

2013

90. Ames D, Ritchie C. Prospective cohort studies in dementia. Int Review Psychiatry. 2013; 25: 647-649.

89. Maruff P, Lim YY, Darby D, Ellis KA, Pietrzak RH, Snyder PJ, Bush AI, Szoeke C, Savage G, Ames D, Masters CL for the AIBL Research Group. Clinical utility of the CogState brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer’s disease. BMC Pharma and Toxicol. 2013; 1: 30.

88. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med Technol. 2013; 41: 11-18.

87. Rowe CC, Villemagne VL. Amyloid imaging with PET in early Alzheimer disease diagnosis. Med Clin North Am. 2013; 97: 377-398.

86. Bourgeat P, Dore V, Villemagne VL, Rowe CC, Salvado O, Fripp J. MilxXplore: a web-based system to explore large imaging datasets. J Am Med Inform Assoc. 2013; 20: 1046-1052.

85. Frost S, Kanagasingam Y, Sohrabi H, Bourgeat P, Villemagne V, Rowe CC, Macaulay SL, Szoeke C, Ellis KA, Ames D, Masters CL, Rainey-Smith S, Martins RN; AIBL Research Group. Pupil response biomarkers for early detection and monitoring of Alzheimer’s disease. Curr Alzheimer Res. 2013; 10: 931-939.

84. Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R, Robins P, Tochon-Danguy H, O’Keefe G, Pike KE, Szoeke C, Salvado O, Macaulay SL, O’Meara T, Head R, Cobiac L, Savage G, Martins R, Masters CL, Ames D &Villemagne VL. Predicting Alzheimer’s disease with beta-amyloid imaging: Results from AIBL. Annals of Neurology. 2013; 74: 905-913.

83. Andrews KA, Modat M, Macdonald KE, Yeatman T, Cardoso MJ, Leung KK, Barnes J, Villemagne VL, Rowe CC, Fox NC, Ourselin S, Schott JM. Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. PloS One. 2013; 8: e58816.

82. Villemagne VL, Rowe CC. Long night’s journey into the day: amyloid beta imaging in Alzheimer’s disease. J Alzheimers Dis. 2013; 33: S349-359.

81. Sona A, Ellis KA, Ames D. Rapid cognitive decline in Alzheimer’s disease: a literature review. Int Review Psychiatry. 2013; 25: 650-658.

80. Ellis KA, Rainey-Smith SR, Rembach A, Macaulay SL, Villemagne VL and the AIBL research group. Enabling a multidisciplinary approach to the study of aging and Alzheimer’s disease: An update from the AIBL study. Int Rev Psychiatry. 2013; 25: 699-710.

79. Rembach A, Hare DJ, Lind M, Fowler CJ, Cherny RA, McLean C, Bush AI, Masters CL, Roberts BR. Decreased copper in Alzheimer’s disease brain is predominantly in the soluble extractable fraction. Int J Alz Disease 2013: 623241.

78. Lim YY, Ellis KA, Harrington K, Pietrzak RH, Gale J, Ames D, Bush AI, Darby D, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Villemagne VL, Maruff P and the AIBL Research Group. Cognitive decline in adults with amnestic mild cognitive impairment and high A-beta amyloid: Prodromal Alzheimer’s Disease. J Alzheimers Dis. 2013; 33: 1167-1176.

77. Lim YY, Ellis KA, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G., Szoeke C, Villemagne VL, Maruff P for the AIBL research group. Aβ amyloid, cognition and APO E genotype in healthy older adults. Alzheimers Dement 2013; 9: 538-545.

76. Rembach A, Ryan TM, Roberts BR, Doecke JD, Wilson WJ, Watt AD, Barnham KJ and Masters CL. Progress towards a consensus biomarker for Alzheimer’s disease: a review of peripheral based analytes. Biomark Med 2013; 7: 641-662.

75. Harrington KD, Lim YY, Ellis KA, Copolov C, Darby D, Weinborn M, Ames D, Martins RN, Savage G, Szoeke C, Rowe C, Villemagne VL, Masters CL, Maruff P. The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI. Int Psychogeriat. 2013; 25: 1667-1677.

74. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch, Karlawish JH, Rowe CC, Hedrick S, Pappas V, Carrillo MC, Hartley DM. Update on appropriate use criteria for Amyloid PET imaging: Dementia experts, mild cognitive impairment and education. Alzheimers Dement 2013; 9: e106-109.

73. Burnham SC, Villemagne VL, Macaulay SL. The AIBL study: opening the presymptomatic window in Alzheimer disease. MJA 2013; 198:578.

72. Foster JK, Albrecht MA, Savage G, Lautenschlager NT,Ellis KA, Maruff P, Szoeke C, Taddei K, Martins R, Masters CL, Ames D and the AIBL Research Group. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle study. Brain 2013; 136: 2201-2216.

71. Brown BM, Peiffer JJ,Taddei K, Lui JK, Laws SM, Gupta VB, Taddei T, Ward VK, Rodrigues MA, Burnham S, Rainey-Smith SR, Villemagne VL, Bush A, Ellis KA, Masters CL, Ames D, Macaulay SL, Szoeke C, Rowe CC, and Martins RN, for the AIBL Research Group. Physical activity and amyloid-β plasma and brain levels: results from the Australian, Imaging, Biomarkers and Lifestyle Study of Ageing. Molec Psych 2013; 18: 875-881

70. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan A, Heegaard N, Hsiung G-YR, Hyman B, Iqbal K, Lachno DR, Lleό, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijick M, Verbeek MM, Zetterberg H, Blennow K; on behalf of the Alzheimer’s Association QC Program Work Group. CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimer’s Dement. 2013; 9: 251-261.

69. Ong K, Villemagne VL, Bahar-Fuchs A, Lamb F, Chételat G, Raniga P, Mulligan RS, Salvado O, Putz B, Roth K, Masters CL, Reininger CB and Rowe CC. 18F-florbetaben Aβ imaging in mild cognitive impairment. Alz Res Therapy 2013; 5: 4.

68. Lim YY, Jaeger J, Harrington K, Ashwood T, Ellis KA, Stoffler A, Szoeke C, Lachovitzki R, Martins RN, Villemagne VL, Bush A, Masters CL, Rowe CC, Ames D, Darby D, Maruff P. Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer’s disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). Archives Clin Neuropsychology. 2013; 28: 320-330.

67. Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, Harrington KD, Bourgeat P, Salvado O, Darby D, Snyder PJ, Bush AI, Martins RN, Masters CL, Rowe CC, Nathan PJ, Maruff P for the AIBL Research Group. BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer’s disease. Neurobiol Aging. 2013; 34: 2457-2464.

66. Buckley R, Saling M, Ames D, Lautenschlager N, Macauley SL, Martins RN, Masters CL, O’Meara T, Rowe CC, Savage G, Szoeke C, Villemagne VL, Ellis KA for the Australian Imaging Biomarkers and Lifesyle Research Group. Factors affecting subjective memory complaints in the AIBL aging study: biomarker, memory, affect and age. IntPsychogeriatr. 2013; 25: 1307-1315.

65. Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, Cselényi Z, Masters CL, Villemagne VL. Head to head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for Aβ imaging in aging and dementia. J Nucl Med 2013; 54: 880-886.

64. Doré V, Villemagne VL, Bourgeat P, Fripp J, Acosta O, Chetélat G, Zhou L, Martins R, Ellis KA, Masters CL, Ames D, Salvado O and Rowe CC. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness and memory in cognitively unimpaired individuals and in Alzheimer’s disease. JAMA Neurol 2013; 70: 903-911.

63. Lim YY, Ellis KA, Harrington K, Kamer A, Pietrzak RH, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeke C, Villemagne V, Ames D, Maruff P, and the AIBL research group. Cognitive consequences of high A-beta amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer’s Disease. Neuropsychology. 2013; 27: 322-332.

62. Frost S, Kanagasingam Y, Sohrabi H, Bourgeat P, Salvado O, Villemagne V, Rowe CC, Macaulay SL, Szoeke C, Ellis KA, Ames D, Masters CL, Rainey-Smith S, Martins RN, and the AIBL research group. Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s Disease. Transl Psychiatry. 2013 Feb 6;3: e233.

61. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL. Amyloid β deposition, neurodegeneration and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013; 12: 357-367 [

60. Lim YY, Pietrzak RH, Ellis KA, Jaeger J, Harrington K, Ashwood T, Szoeke C, Martins RN, Bush AI, Masters CL, Rowe CC, Villemagne VL, Ames D, Darby D, Maruff P. Rapid decline in episodic memory in healthy older adults with high Amyloid-β. J Alz Dis. 2013; 33: 675-679.

59. Carillo MC, Rowe CC, Szoeke C, Masters CL, Ames D, O’Meara T, Macauley L, Milner A, Ellis K, Maruff P, Rainey-Smith SR, Martins RN, Bain LJ, Head RJ. Research and standardization in Alzheimer’s trials: Reaching international consensus. Alzheimers Dement. 2013; 9: 160-168.

58. Ellis KA, Lim YY, Harrington K, Ames D, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeke C, Villemagne VL, Maruff P, AIBL research group. Decline in cognitive function over 18 months in healthy older adults with high A-beta amyloid. J Alzheimers Dis. 2013; 34: 861-871.

57. Rembach A, Doecke J, Roberts B, Duce JA, Faux NG, Volitakis I, Trounson B, Fowler CJ, Pertile KK, Rumble BL, Varghese J, Ellis KA, Rowe CC, Martins RN, Ames D, Masters CL, Bush AI and the AIBL research group. Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer’s disease. J Alzheimers Dis. 2013; 34: 171-182.

2012

56. Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Villemagne VL, Rowe CC, Fripp J and the AIBL Research Group. MR-less Surface-based Amyloid estimation by subject-specific atlas selection and Bayesian fusion. Med Image ComputComput Assist Interv 2012; 15: 220-227.

55. Brown BM, Peiffer JJ, Sohrabi HR, Mondal A, Gupta VB, Rainey-Smith SR, Taddei K, Burnham S, Ellis KA, Szoeke C, Masters CL, Ames D, Rowe CC, Martins RN, and the AIBL research group. Intense physical activity is associated with cognitive performance in the elderly. Transl Psych. 2012 Nov 2; 2: e191.

54. Gardener S, GuY, Rainey-Smith S, Keogh JB, Clifton PM, Mathieson SL, Taddei K, Mondal A, Ward VK, Scarmeas N, Barnes M, Ellis KA, Head R, Masters CL, Ames D, Macaulay L, Rowe CC, Szoeke C, Martins RN and The AIBL Research Group. Adherence to a Mediterranean diet and Alzheimer’s disease risk in an Australian population. Transl Psychiatry. 2012 Oct 2; 2: e164.

53. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam C-P, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, for the Alzheimers’s Disease Neuroimaging Initiative and the Australian Imaging Biomarker and Lifestyle research group. Blood-based protein biomarkers for diagnosis of Alzheimer’s disease. Arch Neurol. 2012; 69:1318-1325 [see also In Reply: Laske C. Blood-based biomarkers in Alzheimer’s disease: where are we now, where have we to go? and Laws SM, Doecke J, Martins RN. In reply:“Blood-based biomarkers in Alzheimer’s disease: where are we now, where have we to go?” – ChristophLaske. Arch Neurol].

52. Cyarto EV, Lautenschlager NT, Desmond PM, Ames D,Szoeke C, Salvado O, Sharman MJ, Ellis KA, Phal PM, Masters CL, Rowe CC, Martins RN and Cox KL. Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial. Bio Med Central Psychiatry 2012; 12: 167.

51. Villemagne VL, Furumoto S, Fodero-Travoletti MT, Harada R, Mulligan RS, Kudo Y, Masters CL, Yanai K, Rowe CC, Okamura N. The challenges of tau imaging. Future Neurol 2012, 7(4):409-421.

50. Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Villemagne VL, Maruff P and the AIBL Research Group. Stronger effect of amyloid load than ApoE genotype on cognitive decline in healthy older adults. Neurology 2012; 79: 1645-1652.

49. Fodero-Travoletti MT, Brockschnieder D, Villemagne VL, Martin L, Connor AR, Thiele A, Berndt M, McLean CA, Krause S, Rowe CC, Masters CL, Dyrks T, Cappai R. In Vitro characterisation of 18F-Florbetaben, an Aβ imaging radiotracer. Nucl Med Biol 2012; 39: 1042-1048.

48. Lim YY, Harrington K, Ames D, Ellis KA, Lachovitzki R, Snyder PJ, Maruff P. Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer’s disease measured using the International Shopping List Test. J ClinExpNeuropsychol 2012 ; 34: 853 – 863.

47. Villain N, Chètelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL and the AIBL research group. Regional dynamics of amyloid-beta deposition in healthy elderly, Mild Cognitive Impairment and Alzheimer’s Disease: a voxelwisePiB-PET longitudinal study. Brain 2012; 135: 2126-2139.

46. Watt AD, Perez KA, Rembach AR, Masters CL, Villemagne VL, Barnham KJ. Variability in blood based amyloid beta assays: The need for consensus on pre-analytical processing. J Alzheimers Dis 2012; 30: 323-336.

45. Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chételat G, O’Keefe G, Jones G, Kung HF, Pontecorvo M, Masters CL, Skovronsky DM, Rowe CC. Differential diagnosis in Alzheimer’s disease and dementia with Lewy bodies via VMAT2 and amyloid imaging. (In: Proceedings of the 10th International Conference on AD/PD 2011. Edited by Nitsch RM, Fisher A, Windisch M, Hanin I.) Neurodegen Dis 2012; 10: 161-165.

44. Acosta O, Fripp J, Dore V, Bourgeat P, Favreau J-M, Chételat G, Rueda A, Villemagne VL, Szoeke C, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Bonner E, Gris F, Xiao D, Raniga P, Barra V, Salvado O. Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer’s disease. J Neurosci Methods 2012; 205: 96-109.

43. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, Chan JG, Young K, Tochon-Danguy H, Masters CL, Rowe CC. Comparison of (11)C-PiB and (18)F-florbetaben for A-beta imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2012; 39: 983-9.

42. Head R, Ames D, Masters CL, Rowe CC, Macaulay SL, and the Australian Imaging Biomarker and Lifestyle study of Ageing. The AIBL study throwing light on amyloid-beta and Alzheimer’s disease. Med J Aust 2012; 196: 376-377.

41. Chètelat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, Rowe CC, and the Australian Imaging Biomarker and Lifestyle study of Ageing (AIBL) Research Group. Relationships between memory performances and β-amyloid deposition at different stages of Alzheimer’s disease. Neurodegener Dis 2012; 10: 141-144.

40. Barber B, Ames D, Ellis K, Martins R, Masters C, and Szoeke C. Lifestyle and late life cognitive health: sufficient evidence to act now?.[Guest Editorial] International Psychogeriatrics 2012; 24: 683-688.

39. Lim YY, Ellis K, Harrington K, Ames D, Martins R, Masters C, Rowe C, Szoeke C, Darby D, Maruff P. Use of CogState brief battery in the assessment of Alzheimer’s disease related cognitive impairment in the Australian Imaging, Biomarker and Lifestyle (AIBL) study. J ClinExpNeuropsychol 2012; 34: 345-58.

38. Chételat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Martins RN, Masters CL, Rowe CC and the AIBL Research Group. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 2012; 78: 477-484.

37. Villemagne VL, Klunk WE, Mathis CA, Rowe CC, Brooks DJ, Hyman BT, Ikonomovic MD, Ishii K, Jack CR, Jagust WJ, Johnson KA, Koeppe RA, Lowe VJ, Masters CL, Montine TJ, Morris JC, Nordberg A, Petersen RC, Reiman EM, Selkoe DJ, Sperling RA, Van Laere K, Weiner MW, Drzezga A. Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2012; 39:209-219.

36. Sona A, Zhang P, Ames D, Bush AI, Lautenschlager NT, Martins R, Masters C, Rowe C, Szoeke C, Taddei K, Ellis K and the AIBL research group. Predictors of rapid cognitive decline in Alzheimer’s disease: results from the Australian, Imaging, Biomarker and Lifestyle (AIBL) study of ageing. International Psychogeriatrics 2012; 24: 197-204.

2011

35. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, IwatsuboT,Jack CR, Kaye J, Montine TJ, ParkDC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo M, Thies B, Morrson-Bogorad M, Wagster MV, Phelps CH.Toward defining the preclinical stages of Alzheimer’s disease: Recommendations of the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimer’s and Dementia 2011; 7: 280-92.

34. Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, Pertile KK, Rembach A, Rowe CC, Rumble RL, Szoeke C, Taddei K, Taddei T, Trounson BO, Villemagne VL, Ward V, Ames D, Masters CL, the AIBL Research Group, Bush AI. Homocysteine, vitamin B12 and folic acid levels in Alzheimer’s disease, mild cognitive impairment and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. J Alzheimers Dis 2011; 27: 909-22.

33. Lambert JC, Dallongeville J, Ellis KA, Schraen-Maschke S, Lui J, Laws S, Dumont J, Richard F, Cottel D, Berr C, Ames D, Masters, CL, Rowe CC, Szoeke C, Tzourio C, Dartigues JF, Buée L, Martins R, Amouyel P. Association of plasma Aβ peptides with blood pressure in the elderly. PLoS One 2011 April 15; 6.

32. Yates PA, Sirisriro R, Villemagne VL, Farquason S, Masters CL, Rowe CC and the AIBL Research Group. Cerebral microhaemorrhage and brain Aβ amyloid in healthy ageing and Alzheimer’s disease. Neurol 2011; 77: 48 – 54.

31. Mattsson N, Andreason U, Persson S, Arai H, Batish D, Bernardini S, Bocchio-Chiavetto L, Blankenstein RA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan A, Forlenza O, Frisoni G, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovitz AZ, Herukka S-K, Holtzman DM, Humpel C, Hyman B, Iqbal K, Jucker M, Kaeser S, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen C, Kummer M, Liu J, Lladó A, Lewczuk P, Li Q-X, Martins R, Masters CL, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine T, Nowatzke W, O’Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen R, Prvulovic D, de Reus HPM, Rissman RA, Scarpini E, Stefani A, Soininen H, Schroder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski J, Tumani H, Umek R, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek M, Windisch M, Zhang J, Zetterberg H, Blennow K. The Alzheimer’s Association external quality control program for CSF biomarkers. Alzheimer’s and Dementia2011; 7: 386–395.

30. Fodero-Tavoletti MT, Villemagne VL, Rowe CC, Masters CL, Barnham KJ, Cappai R. Amyloid-β: The seeds of darkness. Int. J. Biochem Cell Biol2011; 43: 1247-51.

29. Pike KE, Ellis KA, Villemagne VL, Good N, Chételat G, Ames D, Szoeke C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC. Cognition and beta-amyloid in preclinical Alzheimer’s disease: data from the AIBL study. Neuropsychologia 2011; 49: 2384-90.

28. Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor A, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O’Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain 2011; 134: 1089-1100.

27. Watt AD, Perez KA, Faux NG, Pike KE, Rowe CC, Bourgeat P, Salvado O, Masters CL, Villemagne VL, Barnham KJ. Increasing the predictive accuracy of beta-amyloid blood-borne biomarkers in Alzheimer’s disease. J Alzheimers Dis 2011; 24: 47-59.

26. Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, Ames D, O’Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC and the Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group. Independent contribution of temporal A deposition to memory decline in the predementia phase of Alzheimer’s disease. Brain 2011; 134: 798-807.

25. McBride SJ, Szoeke CEI, Good NM, Ames D, Martins RN, Masters CL, Maruff PT, Rowe CC, Savage G, Ellis KA and the AIBL Research Group. A web-based normative data tool for assessing cognitive performance in healthy older Australians. Med J Aust(Supplement) 2011; 194: 512-14.

24. Sittironnarit G, Ames D, Bush AI, Faux N, Flicker L, Foster J, Hilmer S, Lautenschlager NT, Maruff P, Masters CL, Martins RN, Rowe C, Szoeke C, Ellis KA, and the AIBL research group. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. Dement GeriatrCognDisord 2011; 31:173-178.

23. Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, Lui JK, Masters C, Rowe CC, Szoeke C, Taddei K, Martins RN for the AIBL Research Group. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurol 2011; 76: 1091-1098.

22. Lim NK-H, Villemagne VL, Soon CPW, Laughton KM, Rowe CC, McLean CA, Masters CL, Evin G, Li Q-X. Investigation of matrix metalloproteinases, MMP-2 and MMP-9 in plasma reveals a decrease of MMP-2 in Alzheimer’s disease. J Alzheimers Dis2011 Jan 1; 26: 779-86.

21. Ellis KA, Rowe CC, Szoeke CEI, Villemagne VL, Ames D, Chételat G, Martins RN, Masters CL, Fripp J, Acosta O, Raniga P, Bourgeat PT, Salvado O. Advances in structural and molecular neuroimaging in Alzheimer’s disease. Med J Aust(Supplement) 2011; 194: 520-523.

20. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan R, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O’Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC. Longitudinal assesment of Aβ and cognition in aging and Alzheimer’s disease. Ann Neurol 2011; 69: 181-192.

2010

19. Bahar-Fuchs A, Moss S, Pike KE, Villemagne VL, Masters CL, Rowe C, Savage G. Olfactory deficits and A burden in AD, MCI and healthy ageing: a PiB PET Study. J Alzheimers Dis2010; 22: 1081-1087.

18. Rueda A, Acosta O, Couprie M, Bourgeat P, Fripp J, Dowson N, Romero E, Salvado O. Topology-corrected segmentation and local intensity estimates for improved partial volume classification of brain cortex in MRI. J Neurosci Methods 2010; 188: 305-315.

17. Chételat G, Villemagne VL, Pike KE, Baron J-C, Bourgeat P, Jones G, Faux NG, Ellis KA, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC and Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010; 133: 3349-3358.

16. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O’Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010: 31; 1275-1283.

15. Lui JK, Laws SM, Li Q-X, Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K, Dromey J, Ellis KA, Faux NG, Foster J, Fowler C, Gupta V, Hudson P, Laughton K, Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ward V, Martins RN for the AIBL Research Group. Plasma amyloid-β as a biomarker in Alzheimer’s Disease: The AIBL Study of Aging. J Alzheimers Dis 2010; 20; 1233-1242.

14. Chételat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, Szoeke C, Martins RN, O’Keefe GJ, Salvado O, Masters CL, Rowe CC and the Australian Imaging Biomarkers and Lifestyle Research Group. Relationship between atrophy and β-amyloid deposition in Alzheimer disease. Ann Neurol2010; 67: 317-324.

13. Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR, Bourgeat P, Salvado O, Bedo J, Hutton CA, Faux NG, Masters CL, Barnham KJ. Blood borne amyloid- dimer correlates with clinical markers of Alzheimer’s disease. J Neurosci2010; 30: 6315-6322.

12. Ellis KA, Rowe CC, Villemagne VL, Martins RN, Masters CL, Salvado O, Szoeke C, Ames D and the AIBL Research group. Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle Study: Collaboration with the Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s & Dementia 2010; 6: 291-296.

11. Bourgeat P, Chételat G, Villemagne VL, Fripp J, Raniga P, Pike K, Acosta O, Szoeke C, Ourselin S, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Salvado O on behalf of the AIBL Research Group. β-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010; 74: 121-127.

2009

10. Bates KA, Verdile G, Li Q-X, Ames D, Hudson P, Masters CL and Martins RN. Clearance mechanisms of Alzheimer’s amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 2009; 14: 469-486

9. Acosta O, Bourgeat P, Fripp J, Zuluaga MA, Fripp J, Salvado O, Ourselin S. Automated voxel-based 3D cortical thickness measurement in a combined Lagrangian-Eulerian PDE approach using partial volume maps. Medical Image Analysis 2009; 13: 730-743.

8. Okamura N, Fodero-Tavoletti MT, Kudo Y, Rowe CC, Furumoto S, Arai H, Masters CL, Yanai K, Villemagne VL. Advances in molecular imaging for the diagnosis of dementia. Expert Opin Med Diagn 2009; 3: 705-716.

7. Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O’Keefe GJ, Masters CL, Mori H, Rowe CC. High striatal amyloid -peptide deposition across different autosomal Alzheimer’s disease mutation types. Arch Neurol 2009; 66: 1537-1544.

6. Fodero-Tavoletti MT, Rowe CC, McLeanCA, Leone L, Li Q-X, Masters CL, Cappai R, Villemagne VL. Characterization of PiB binding to white matter in AD and other dementias. J Nucl Med 2009; 50: 198-204.

5. Fodero-Tavoletti MT, Cappai R, McLean CA, Pike KE, Adlard PA, Cowie T, Connor AR, Masters CL, Rowe CC, Villemagne VL. Amyloid imaging in Alzheimer’s disease and other dementias. Brain ImagBehav 2009; 3: 246-261.

4. Ellis, K.A., Bush, A.I., Darby, D., De Fazio, D., Foster, J., Hudson, P., Lautenschlager, N.T., Lenzo, N., Martins, R.N., Maruff, P., Masters, C.L., Milner, A., Pike, K., Rowe, C.C., Savage, G., Szoeke, C., Taddei, K., Villemagne, V.L., Woodward, M., Ames, D. and the AIBL Research Group. (2009). The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. International Psychogeriatrics, 21, 672-687.

2008

3. Fripp, J., Bourgeat, P., Acosta, O., Raniga, P., Modat, M,, Pike, K.E., Jones, G., O’Keefe, G., Masters, C.L., Ames, D., Ellis, K., Maruff, P., Currie, J., Villemagne, V.L., Rowe, C.C., Salvado, O. and Ourselin, S. (2008). Appearance modelling of C11 PiB PET images: characterizing amyloid deposition in Alzheimer’s disease, mild cognitive impairment and healthy aging. Neuroimage, 43, 430-439

2007

2. Ng, S., Villemagne, V.L., Berlangieri, S., Lee, S-T., Cherk, M., Gong, S.J., Ackermann, U., Saunder, T., Tochon-Danguy, H., Jones, G., Smith, C., O’Keefe, G., Masters, C.L., Rowe, C.C. (2007). Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s Disease. Journal of Nuclear Medicine, 48, 547-552.

1. Rowe, C.C., Ng S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T.F., Dickinson K.L., Maruff. P., Darby, D., Smith, C., Woodward, M., Merory, J., Tochon-Danguy, H., O’Keefe, G., Klunk, W.E., Mathis, C.A., Price, J.C., Masters, C.L. and Villemagne, V.L. (2007). Imaging β-amyloid burden in aging and dementia. Neurology, 68, 1718-1725.

© Copyright AIBL - Theme by Pexeto